In specific relation to breast cancer, an earlier study assessed the anti-tumour-enhancing effects of trastuzumab (Herceptin), a recombinant monoclonal antibody, when combined with NaB against a HER2-overexpressing breast cancer cell line [24]. This evidence concerns the gene ERBB2 and breast carcinoma.